10.63
+0.34(+3.30%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
100
First IPO Date
October 20, 2020
| Name | Title | Pay | Year Born |
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Chief Executive Officer & Director | 1.3M | 1977 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 987,868 | 1988 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 1.3M | 1966 |
| Luciana Marques | Director of HR, People & Culture | 0 | N/A |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | 0 | N/A |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | 0 | N/A |
| Ms. Nuala Brennan | Chief Clinical Development Officer | 0 | N/A |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | 0 | N/A |
| Mr. Oliver Daltrop Ph.D. | Chief Operations Officer | 0 | N/A |
| Joana Cortez | Senior Director Legal & Compliance | 0 | N/A |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.